Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...
Trovagene is a clinical-stage, oncology therape...
Abiomed (NASDAQ: ABMD) is a leading provider of medical devices that provide circu...
Abiomed (NASDAQ: ABMD) is a leading provider of...
BioLife Solutions is the leading developer, manufacturer and supplier of proprieta...
BioLife Solutions is the leading developer, man...
Verrica Pharmaceuticals Inc. is an innovative clinical-stage medical dermatology c...
Verrica Pharmaceuticals Inc. is an innovative c...
Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...
Neurocarrus is developing a breakthrough therap...
Acceleron is dedicated to the discovery and development of innovative, life-changi...
Acceleron is dedicated to the discovery and dev...
Vir integrates diverse innovations in science, technology, and medicine to transfo...
Vir integrates diverse innovations in science, ...
Join the National Investor Network and get the latest information with your interests in mind.